Cabozantinib for the Management of Metastatic Clear Cell Renal Cell Carcinoma

Sharon Del Vecchio, Robert J Ellis

Abstract


Cabozantinib is a multi-tyrosine kinase inhibitor used for the treatment of various solid-organ tumours. It was recently approved as a first- and second-line therapeutic for the management of advanced/metastatic renal cell carcinoma based on the results of two randomised controlled trials. The phase III METEOR trial compared cabozantinib against everolimus as a second- or greater line therapy and found benefits in progression-free and overall survival, and the phase II CABOSUN trial compared cabozantinib against sunitinib as a first-line therapeutic and found benefits in terms of progression-free survival. This review briefly summarises how cabozantinib fits into current treatment paradigms for the management of advanced renal cell carcinoma.


Keywords


cabozantinib; first-line therapy; metastatic renal cell carcinoma; second-line therapy

Full Text:

HTML PDF XML


DOI: http://dx.doi.org/10.15586/jkcvhl.2018.109

Article Metrics

Metrics Loading ...




Copyright (c) 2018 Sharon Del Vecchio, Robert J Ellis

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.